RhumbLine Advisers’s Janux Therapeutics JANX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.37M | Buy |
59,391
+16,741
| +39% | +$387K | ﹤0.01% | 2092 |
|
|
2025
Q1 | $1.15M | Buy |
42,650
+4,497
| +12% | +$121K | ﹤0.01% | 2101 |
|
|
2024
Q4 | $2.04M | Buy |
38,153
+599
| +2% | +$32.1K | ﹤0.01% | 1865 |
|
|
2024
Q3 | $1.71M | Sell |
37,554
-454
| -1% | -$20.6K | ﹤0.01% | 1994 |
|
|
2024
Q2 | $1.59M | Buy |
38,008
+11,085
| +41% | +$464K | ﹤0.01% | 2004 |
|
|
2024
Q1 | $1.01M | Buy |
26,923
+838
| +3% | +$31.6K | ﹤0.01% | 2242 |
|
|
2023
Q4 | $280K | Sell |
26,085
-447
| -2% | -$4.8K | ﹤0.01% | 3011 |
|
|
2023
Q3 | $267K | Sell |
26,532
-246
| -0.9% | -$2.48K | ﹤0.01% | 2989 |
|
|
2023
Q2 | $318K | Sell |
26,778
-71
| -0.3% | -$843 | ﹤0.01% | 2971 |
|
|
2023
Q1 | $325K | Buy |
26,849
+1,158
| +5% | +$14K | ﹤0.01% | 2586 |
|
|
2022
Q4 | $338K | Buy |
25,691
+111
| +0.4% | +$1.46K | ﹤0.01% | 2630 |
|
|
2022
Q3 | $346K | Buy |
25,580
+1,678
| +7% | +$22.7K | ﹤0.01% | 2669 |
|
|
2022
Q2 | $292K | Buy |
23,902
+7,686
| +47% | +$93.9K | ﹤0.01% | 2767 |
|
|
2022
Q1 | $233K | Buy |
16,216
+5,179
| +47% | +$74.4K | ﹤0.01% | 2719 |
|
|
2021
Q4 | $218K | Sell |
11,037
-73
| -0.7% | -$1.44K | ﹤0.01% | 2812 |
|
|
2021
Q3 | $240K | Buy |
+11,110
| New | +$240K | ﹤0.01% | 2848 |
|